IBDEI0KQ ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10159,0)
 ;;=201.90^^67^672^83
 ;;^UTILITY(U,$J,358.3,10159,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10159,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,10159,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,10159,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,10160,0)
 ;;=785.6^^67^672^89
 ;;^UTILITY(U,$J,358.3,10160,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10160,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,10160,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,10160,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,10161,0)
 ;;=200.20^^67^672^90
 ;;^UTILITY(U,$J,358.3,10161,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10161,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,10161,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,10161,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,10162,0)
 ;;=202.00^^67^672^92
 ;;^UTILITY(U,$J,358.3,10162,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10162,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,10162,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,10162,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,10163,0)
 ;;=200.10^^67^672^91
 ;;^UTILITY(U,$J,358.3,10163,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10163,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,10163,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,10163,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,10164,0)
 ;;=273.3^^67^672^93
 ;;^UTILITY(U,$J,358.3,10164,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10164,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,10164,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,10164,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,10165,0)
 ;;=203.00^^67^672^103
 ;;^UTILITY(U,$J,358.3,10165,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10165,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,10165,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,10165,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,10166,0)
 ;;=203.01^^67^672^105
 ;;^UTILITY(U,$J,358.3,10166,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10166,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,10166,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,10166,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,10167,0)
 ;;=238.6^^67^672^108
 ;;^UTILITY(U,$J,358.3,10167,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10167,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,10167,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,10167,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,10168,0)
 ;;=205.00^^67^672^4
 ;;^UTILITY(U,$J,358.3,10168,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10168,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,10168,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,10168,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,10169,0)
 ;;=205.01^^67^672^6
 ;;^UTILITY(U,$J,358.3,10169,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10169,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,10169,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,10169,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,10170,0)
 ;;=205.10^^67^672^19
 ;;^UTILITY(U,$J,358.3,10170,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10170,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,10170,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,10170,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,10171,0)
 ;;=205.11^^67^672^21
 ;;^UTILITY(U,$J,358.3,10171,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10171,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,10171,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,10171,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,10172,0)
 ;;=289.0^^67^672^55
 ;;^UTILITY(U,$J,358.3,10172,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10172,1,4,0)
 ;;=4^289.0
